Skip to main content

Peer Review reports

From: A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial

Original Submission
10 Jun 2022 Submitted Original manuscript
22 Jul 2022 Author responded Author comments - Yohei Chiba
Resubmission - Version 2
22 Jul 2022 Submitted Manuscript version 2
Publishing
29 Jul 2022 Editorially accepted
9 Aug 2022 Article published 10.1186/s12885-022-09949-8

You can find further information about peer review here.

Back to article page